ZGEN - BMO MSCI Genomic Innovation Index ETF

Download Fact Sheet

Portfolio Strategy

The BMO MSCI Genomic Innovation Index ETF (ZGEN) has been designed to replicate, to the extent possible, the performance of the MSCI ACWI IMI Genomic Innovation Index, net of expenses. The Fund captures this mega trend by investing in stocks that have high exposure to innovative genomic companies. The Fund invests in and holds the Constituent Securities of the Index in the same proportion as they are reflected in the Index.

Benchmark Info

The MSCI ACWI IMI Genomic Innovation Index, developed in collaboration with ARK Invest, is based on the MSCI ACWI IMI Index, which includes large, mid and small capitalization companies across developed and emerging markets. The Index aims to capture the performance of companies which have significant revenues from the development of new products and services in the field of genomic sequencing, synthesis, analysis or instrumentation, enable bio computing, bioinformatics, molecular diagnostics and agricultural biotechnology. Securities are assigned revenue linked relevance scores, and the securities in the Index are weighted by a combination of their relevance score and their market capitalization. The Index rebalances semi-annually in May and November.

Benefits

  • Designed for investors looking for growth solutions
  • Exposure to the global mega trend of genomic innovation
  • Benefits from local currency appreciation
  • Professionally managed by BMO Global Asset Management

Full details: ZGEN - BMO MSCI Genomic Innovation Index ETF

Latest insights

No posts matching your criteria